$18.41
-0.19 (-1.02%)
Open$18.60
Previous Close$18.60
Day High$19.12
Day Low$18.05
52W High$65.80
52W Low$5.80
Volume—
Avg Volume1.19M
Market Cap809.00M
P/E Ratio—
EPS$-293.09
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+88.7% upside
Current
$18.41
$18.41
Target
$34.74
$34.74
$25.90
$34.74 avg
$38.60
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 29.07M | 27.10M | 30.53M |
| Net Income | 5.84M | 4.59M | 6.02M |
| Profit Margin | 20.1% | 16.9% | 19.7% |
| EBITDA | 8.15M | 7.65M | 7.71M |
| Free Cash Flow | 6.21M | 7.09M | 6.33M |
| Rev Growth | +18.1% | +12.4% | +4.7% |
| Debt/Equity | 0.64 | 0.68 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |